NEWARK, CA / ACCESSWIRE / December 13, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced it has…
Positive initial data and clean safety profile catalyze optimization planSize of both ongoing clinical trials significantly increasedLower dose eliminated from…
REDWOOD CITY, CA / ACCESSWIRE / December 13, 2023 / Juva Life Inc. (CSE:JUVA)(OTCQB:JUVAF)(FRANKFURT:4VV) ("Juva Life" or the "Company"), Juva…
Investment Round will Fund Expansion of Commercial Team and Further Product DevelopmentPLEASANTON, Calif.--(BUSINESS WIRE)--#CVAC--Calyxo, Inc., a medical device company developing…
Health Care Service Corporation, Laerdal Million Lives Fund, BayCare, Parkview Health, University of Chicago Medicine, Organon and Stryker to support…
Novel Results Published in Respected Peer-Reviewed Food Science and Emerging Technologies Journal - Discussions Underway with Beverage Industry CompaniesSOUTH EASTON,…
Long term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new…
Following the successful TREK-AD Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, process is underway to identify potential partners.…
Long term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new…
NORTHVALE, NJ / ACCESSWIRE / December 12, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical…